Lyell Immunopharma (LYEL) Change in Accured Expenses (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Change in Accured Expenses data on file, last reported at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 63.56% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (up 80.88% YoY), and the FY2025 full-year result was -$7.6 million, down 511.36% from the prior year.
• Change in Accured Expenses fell to -$3.6 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.4 million in Q4 2022 to a low of -$9.8 million in Q1 2025.
• A 5-year average of -$802411.8 and a median of -$766000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 491.07% in 2025, while the deepest fall reached 745.35% in 2025.
• Tracing LYEL's Change in Accured Expenses over 5 years: stood at $5.4 million in 2022, then plunged by 132.37% to -$1.7 million in 2023, then advanced by 27.89% to -$1.3 million in 2024, then jumped by 491.07% to $4.9 million in 2025, then tumbled by 172.74% to -$3.6 million in 2026.
• Business Quant data shows LYEL's Change in Accured Expenses at -$3.6 million in Q1 2026, $4.9 million in Q4 2025, and $572000.0 in Q3 2025.